The blood-brain/tumor barriers: Challenges and chances for malignant gliomas targeted drug delivery

Current Pharmaceutical Biotechnology

Volumn 13, Issue 12, 2012, Pages 2380-2387

  Zhan, Changyou ^a   Lu, Weiyue ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Blood brain barrier; Blood tumor barrier; Gliomas; Targeted drug delivery system; Therapy

Indexed keywords

ACLARUBICIN; ANTINEOPLASTIC AGENT; CHLOROTOXIN; DAUNORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; IMMUNOLIPOSOME; INTEGRIN; INTERLEUKIN 13 RECEPTOR; LIPOSOME; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BLOOD TUMOR BARRIER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; NANOENCAPSULATION; NANOPROBE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS;

EID: 84867717316     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112803341798     Document Type: Article

References (61)

1. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumors of the central nervous system. Acta. Neuropathol., 2007, 114, 97-109.
2. Wen, P.Y.; and Kesari, S. Malignant gliomas in adults. N. Engl. J. Med., 2008, 359, 492-507.
3. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352, 987-996.
4. Xie, H.; Xue, Y.X.; Li, L.B.; Liu, Y.H. Endothelial-monocyteactivating polypeptide II increases blood-tumor barrier permeability by down-regulating the expression levels of tight junction associated proteins. Brain Res., 2010, 1319, 13-20.
5. Laquintana, V; Trapani, A.; Denora, N.; Wang, F.; Gallo, J.M.; Trapani, G. New stategies to deliver anticancer drugs to brain tumors. Exp. Oppin. Drug Deliv., 2009, 6, 1017-1032.
6. Pardridge, W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Intervent., 2003, 3, 90-105.
7. Abbott, N.J.; Rönnbäck, L.; and Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7, 41-53.
8. Schlageter, K.E.; Molnar, P.; Lapin, G.D.; Groothuis, D.R. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structure and functional properties. Microvasc. Res., 1999, 58, 312-328.
9. Sarin, H.; Kanevsky, A.S.; Wu, H.; Brimacombe, K.R.; Fung, S.H.; Sousa, A.A.; Auh, S.; Wilson, C.M.; Sharma, K.; Aronova, M.A.; Leapman, R.D.; Griffiths, G.L.; Hall, M.D. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Transl. Med., 2008, 6, 80.
10. Roberts, W.G.; Delaat, J.; Nagane, M.; Huang, S.; Cavenee, W.K.; Palade, G.E. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am. J. Path., 1998, 153, 1239-1248.
11. Vick, N.A.; Bigner, D.D. Microvascular abnormalities in virallyinduced canine brain tumors. structural bases for altered bloodbrain barrier function. J. Neurol. Sci., 1972, 17, 29-39.
12. Hobbs, S.K.; Monsky, W.L.; Yuan F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA., 1998, 95, 4607-4612.
13. Sarin, H.; Kanevsky, A.S.; Wu, H.; Sousa, A.A.; Wilson, C.M.; Aronova, M.A.; Griffiths, G.L.; Leapman, R.D.; Vo, H.Q. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J. Transl. Med., 2009, 7, 51.
14. Verhoeff, J.J.; van Tellingen, O.; Claes, A.; Stalpers, L.J.; van Linde, M.E.; Richel, D.J.; Leenders, W.P.; van Furth, W.R. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer, 2009, 9, 444.
15. Ewing, J.R.; Brown, S.L.; Lu, M.; Panda, S.; Ding, G.; Knight, R.A.; Cao, Y.; Jiang, Q.; Nagaraja, T.N.; Churchman, J.L.; Fenstermacher, J.D. Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J. Cereb. Blood flow Metab., 2006, 26, 310-320.
16. Muldoon, L.L.; Soussain, C.; Jahnke, K.; Johanson, C.; Siegal, T.; Smith, Q.R.; Hall, W.A.; Hynynen, K.; Senter, P.D.; Peereboom, D.M.; Neuwelt, E.A. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol., 2007, 25, 2295-2305.
17. Weller, M. Angiogensis in glioblastoma: just another moving target? Brain, 2010, 133, 955-956.
18. Ali, M.M.; Janic, B.; Babajani-Feremi, A.; Varma, N.R.; Iskander, A.S.; Anagli, J.; Arbab, A.S. Changes in vascular permeability and expression of different angiogenic factors following antiangiogenic treatment in rat glioma. PLOS One, 2010, 5, e8727.
19. Yano, S.; Kondo, K.; Yamaguchi, M.; Richmond, G.; Hutchison, M.; Wakeling, A.; Averbuch, S.; Wadsworth, P. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res., 2003, 23, 3639-3650.
20. Spano, J.P.; Fagard, R.; Soria, J.C.; Rixe, O.; Khayat, D.; Milano, G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann. Oncol., 2005, 16, 189-194.
21. Fondell, A.; Edwards, K.; Ickenstein, L.M.; Sjberg, S.; Carlsson, J.; Gedda, L. Nuclisome: a novel concept for radionuclide therapy using targeting liposomes. Eur. J. Nucl. Mol. Imaging, 2010, 37, 114-123.
22. Baulida, J.; Kraus, M.H.; Alimandi, M.; Di Fiore, P.P.; Carpenter, G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem., 1996, 271, 5251-5257.
23. Feng, B.; Tomizawa, K.; Michiue, H.; Han, X.J.; Matsui, H. Developmemnt of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo. Biomaterials., 2010, 31, 4139-4145.
24. Liotta, L.A.; Steeg, P.S.; Stetler-Stevenson, W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991, 64, 327-336.
25. Woessner, J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J., 1991, 5, 2145-2154.
26. Hibbs, M.S.; Hoidal, J.R.; Kang, A.H. Expression of a metalloproteinase that degrades native type collagen and denatured collagens by cultured human alveolar macrophages. J. Clin. Inves., 1987, 80, 1644-1650.
27. Senior, R.M.; Griffin, G.L.; Fliszar, C.J.; Shapiro, S.D.; Goldberg, G.I.; Welgus, H.G. Human 92-and 72-kilodalton type collagenases are elastases. J. Biol. Chem., 1991, 266, 7870-7875.
28. Liotta, L.A.; Stetler-Stevenson, W.G. Metalloproteinases and cancer invasion. Semin. Cancer Biol., 1990, 1, 99-106.
29. Sawaya, R.E.; Yamamoto, M.; Gokaslan, Z.L.; Wang, S.W.; Mohanam, S.; Fuller, G.N.; Mc Cutcheon, I.E.; Stetler-Stevenson, W.G.; Nicolson, G.L.; Rao, J.S. Expression and localization of 72 kDa type collagenase (MMP-2) in human malignant gliomas in vivo. Clin. Exper. Metast., 1995, 14, 35-42.
30. DeBin, J.A.; Strichartz, G.R. Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon., 1991, 29, 1403-1408.
31. Soroceanu, L.; Gillespie, Y.; Khazaeli, M.B.; Sontheimer, H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res., 1998, 58, 4871-4879.
32. Lyons, S.A.; O'Neal, J.; Sontheimer, H. Chlorotoxin, a scorpionderived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia., 2002, 39, 162-173.
33. Deshane, J.; Garner, C.C.; Sontheimer, H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem., 2003, 278, 4135-4144.
34. Orndorff, R.L.; Rosenthal, S.J. Neurotoxin quantum dot conjugates detect endogenous targets expressed in liver cancer cells. Nano Lett., 2009, 9, 2589-2599.
35. Veiseh, M.; Gabikian, P.; Bahrami, S.B.; Veiseh, O.; Zhang, M.; Hackman, R.C.; Ravanpay, A.C.; Stroud, M.R.; Kusuma, Y.; Hansen, S.J.; Kwok, D.; Munoz, N.M.; Sze, R.W.; Grady, W.M.; Greenberg, N.M.; Ellenbogen, R.G.; Olson, J.M. Tumor paint: A chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res., 2007, 67, 6882-6888.
36. Veiseh, O.; Kievit, F.M.; Gunn, J.W.; Ratner, B.D.; Zhang, M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials, 2009, 30, 649-657.
37. Paulus W.; Tonn J.C. Basement membrane invasion of glioma cells mediated by integrin receptors. J. Neurosurg., 1994, 80, 515-519.
38. 5 integrin expression in glioma periphery. Neurosurg., 2001, 29, 380-389.
39. 3 for angiogenesis. Science, 1994, 264, 569-571.
40. Friedlander, M.; Brooks, P.C.; Shaffer, R.W.; Kincaid, C.M.; Varner, J.A.; Cheresh, D.A. Definition of two angiogenic pathwaysby distinct av integrins. Science, 1995, 270, 1500-1502.
41. 3 integrin for a new cancer therapy. Angew. Chem. Int. Ed., 1997, 36, 1374-1389.
42. Kim, S.; Bell, K.; Mousa, S.A.; Varner, J.A. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cellbinding domain of fibronectin. Am. J. Pathol., 2000, 156, 1345-1362.
43. Chen, X.; Park, R.; Khankaldyyan, V.; Gonzales-Gomez, I.; Tohme, M.; Moats, R.A.; Bading, J.R.; Laug, W.E.; Conti, P.S. Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. Mol. Imaging Biol., 2006, 8, 9-15.
44. Zhan, C.; Gu, B.; Xie, C.; Li J, Liu, Y.; Lu, W. Cyclic RGD conjugated poly(ethylene glycol)-b-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control. Release, 2010, 143, 136-142.
45. Kimura, R.H.; Cheng, Z.; Gambhir, S.S.; Cochran, J.R. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res., 2009, 69, 2435-2442.
46. M.J., Aman, N., Tayebi, N.I., Obiri, cDNA cloning and characterization of the human interleukin 13 receptor chain. J. Biol. Chem., 1996, 271, 29265-29270.
47. P.J., Lupardus, M.E., Birnbaum, and K.C., Garcia, Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-12 and IL-13R_2. Structure, 2010, 18, 332-342.
48. Hilton, D.J.; Zhang, J.G.; Metcalf, D.; Alexander, W.S.; Nicola, N.A.; Willson, T.A. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA, 1996, 93, 497-501.
49. Madhankumar, A.B.; Slagle-Webb, B.; Wang, X.; Yang, Q.X.; Antonetti, D.A.; Miller, P.A.; Sheehan, J.M.; Connor, J.R. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther., 2009, 8, 648-654.
50. Joshi, B.H.; Puri, R.K.; IL-13 receptor-alpha 2: a novel target for cancer therapy. Immunother., 2009, 1, 321-327.
51. Kioi, M.; Kawakami, M.; Shimamura, T.; Husain, S.R.; Puri, R.K. Interleukin-13 receptor β2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer, 2006, 107, 1407-1418.
52. Mintz, A.; Gibo, D.M.; Slagle-Webb, B.; Christensen, N.D.; Debinski, W. IL-13R alpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia, 2002, 4, 388-399.
53. Madhankumar, A.B.; Slagle-Webb, B.; Mintz, A.; Sheehan, J.M.; Connor, J.R. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther., 2006, 5, 3162-3169.
54. de Vries, N.A.; Beijnen, J.H.; Boogerd, W.; van Tellingen, O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev. Neurother., 2006, 6, 1199-1209.
55. Lu, W.; Sun, Q.; Wan, J.; She, Z.J.; Jiang, X.G. Cationic albuminconjugated pegylated nanoparticles allow gene delivery into brain tumore via intravenous administration. Cancer Res., 2006, 66, 11878-11887.
56. Lu, W.; Wan, J.; Zhang, Q.; She, Z.J.; Jiang, X.G. Aclarubicinloaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Int. J. Cancer, 2007, 120, 420-431.
57. Ying, X.; Wen, H.; Lu, W.L.; Du, J.; Guo, J.; Tian, W.; Men, Y.; Zhang, Y.; Li, R.J.; Yang, T.Y.; Shang, D.W.; Lou, J.N.; Zhang, L.R.; Zhang, Q. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Control Release, 2010, 141, 183-192.
58. Veiseh, O.; Sun, C.; Fang, C.; Bhattarai, N.; Gunn1, J.; Kievit, F.; Du, K.; Pullar, B.; Lee, D.; Ellenbogen, R.G.; Olson, J.; Zhang, M. Specific targeting of brain tumors with an optical/magnetic resonace imaging nanoprobe across the blood-brain barrier. Cancer Res., 2009, 69, 6200-6207.
59. Kascakova, S.; Nadova, Z.; Mateasik, A.; Mikes, J.; Huntosova, V.; Refregiers, M.; Sureau, F.; Maurizot, J.C.; Miskovsky, P.; Jancura, D. High level of low-density lipoprotein receptors enhance hypericin uptake by U-87 MG cells in the presence of LDL. Photochem. Photobiol., 2008, 84, 120-127.
60. Nikanjarn, M.; Gibbs, A.R.; Hunt, C.A.; Budinger, T.F.; Forte, T.M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control Release, 2007, 124, 163-171.
61. Mousazadeh, M.; Palizban, A.; Salehi, R.; Salehi, M. Gene delivery to brain cells with apoprotein E derived peptide conjugated to polylysine (apoEdp-PLL). J. Drug Target, 2007, 15, 226-230.